



CLINICAL PRACTICE GUIDELINE

NIPT Prenatal Testing for Fetal Aneuploidy

This document should be read in conjunction with the [Disclaimer](#)

Aim

To describe NIPT and its place in antenatal aneuploidy screening to assist medical staff and their patients make an informed decision about its use.

Background

Non-invasive Prenatal Testing (NIPT) uses cell-free DNA of placental origin in the maternal serum to screen for fetal aneuploidy. Multiple independent studies have demonstrated the clinical validity of maternal plasma cell-free DNA sequencing for the detection of fetal trisomy 21 in high risk women. The NEXT trial, published in 2015, has subsequently demonstrated the same high performance characteristics in low-risk women. Cell-free DNA based NIPT has high sensitivity (>99.5%) and specificity(99.8%) as a screening test for trisomy 21 with an overall positive predictive value of 80% (compared with 3.4% for combined First Trimester Screening).

Key Points


1. NIPT is not a diagnostic test and high risk results still require confirmation with an invasive test e.g. amniocentesis or CVS.
2. A routine 12 - 14 week gestation ultrasound scan is still required if NIPT is undertaken to assess for multiple pregnancy and major fetal abnormalities (e.g. anencephaly).
3. Currently there is no Medicare funding or private health insurance rebate for NIPT.aneuploidy screening and NIPT has significant direct costs to the patient (\$395-695, depending on the specific provider used) and has a turn-around time of approximately 7-14 days.
4. The results report a risk assessment for trisomy 21, 18 and 13.
5. It can also report on the sex of the fetus and some sex chromosome abnormalities although the performance characteristics are lower than for autosomes

6. Maternal serum can be collected from 10 weeks gestation.
7. There is a test failure rate of up to 5% (this is higher as body mass index increases: the test failure rate is likely to be 50% at a maternal weight of 160kg). In women with test failure there is an increased risk of aneuploidy (6-fold increase in a low risk population).
8. NIPT can be used in twin pregnancies but will only test for trisomies 21,18 and 13. The performance characteristics are lower in twin pregnancies than in singleton pregnancies.
9. NIPT has not been validated for triplet or higher order multiple pregnancies.
10. The laboratory must be advised of the presence of a non-viable fetus together with a viable twin.
11. NIPT is not the appropriate test for aneuploidy if there are fetal abnormalities present on ultrasound. In this circumstance a CVS or amniocentesis should be performed

Pre Screening Counselling

Counselling prior to testing should include

- The sensitivity rate.
- The positive predictive value- this is influenced by test performance and population prevalence and may be as low as 50% for some aneuploid conditions.
- The reported “99%” probability for high risk results is a description of the test and is not equivalent to the positive predictive value which is dependent upon both test and patient factors
- The screening only covers trisomies 21,18 and 13 and X and Y chromosomes (although some laboratories are now offering testing for other aneuploidies such as trisomy 9,16 and 22 and microdeletion / duplication syndromes such as DiGeorge Syndrome ,Prader-Willi / Angelman Syndrome).
- The accuracy of sex determination is 99%
- Any abnormal results will require invasive testing i.e. amniocentesis or CVS
- The approximate cost to the patient.

Keywords:	NIPT, fetal, Aneuploidy, trisomies, ultrasound, maternal, trisomy, abnormality		
Document owner:	OGCCU		
Author / Reviewer:	Evidence Based Clinical Guidelines Co-ordinator		
Date first issued:	June 2016		
Last reviewed:		Next review date:	June 2019
Endorsed by:	OGCCU Management Committee	Date:	13.7.2016
Standards Applicable:	NSQHS Standards: 1  Clinical Care is Guided by Current Best Practice		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.</p>			